The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases.
This technology includes an innovative gene therapy approach aimed at treating retinal diseases, which are a leading cause of vision loss. Retinal diseases, such as age-related macular degeneration and retinitis pigmentosa, affect millions of people worldwide and currently have limited treatment options. Our gene therapy targets the underlying genetic causes of these diseases, offering a potential cure rather than just symptomatic relief.
The technical solution involves the use of adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to retinal cells. This method is significant because it not only addresses the root cause of the disease but also has the potential for long-lasting effects, reducing the need for frequent treatments. You should care about this technology because it represents a breakthrough in the field of ophthalmology, with the potential to restore vision and improve the quality of life for patients suffering from debilitating retinal conditions.
We are seeking licensing partners who are interested in co-developing this groundbreaking technology. The ideal partner would have experience in gene therapy and a commitment to advancing innovative treatments in ophthalmology. We are open to discussions regarding collaboration and are eager to explore opportunities that align with our goals for this technology.